MASSACHUSETTS GENERAL HOSPITAL

University of Colorado Anschutz Medical Campus receives $7 million federal award to establish a Biostatistics Research Center (BRC) focused on understanding the roots of Type 2 diabetes. The BRC, led by four researchers, will support a consortium of four study sites and aims to subtype diabetes based on patient characteristics, incorporating social factors and exploring new biomarkers for better prevention, diagnosis, and treatment.

Proton beam therapy and IMRT yield similar tumor control and quality of life outcomes in low- and intermediate-risk prostate cancer patients, according to the PARTIQoL trial presented at ASTRO Annual Meeting.

A study by NIH's RECOVER Initiative and NYU Langone Health found no reliable biomarkers in routine clinical lab tests for diagnosing long COVID, highlighting the need for further research beyond standard methods.

Proton beam therapy (PBT) and intensity modulated radiation therapy (IMRT) showed no significant differences in patient-reported function outcomes and progression-free survival (PFS) for localized prostate cancer, according to the PARTIQoL trial presented at ASTRO 2024. Both methods achieved excellent quality of life and effective tumor control, with no measurable differences in efficacy outcomes.

Pfizer's sudden withdrawal of Oxbryta, a sickle cell disease drug, raises concerns over patient trust and treatment safety. The abrupt removal, following European regulatory flags, poses risks like severe anemia if patients stop abruptly. Pfizer's lack of transparency and the FDA's limited notice add to the uncertainty, potentially impacting future sickle cell treatments and clinical trials.

The FDA approved Cobenfy, a new antipsychotic medication for schizophrenia, developed by Karuna Therapeutics. Despite its efficacy in clinical trials, concerns about insurance coverage and high list price ($22,500/year) may limit patient access. Bristol Myers Squibb, which acquired Karuna, plans to expand Cobenfy's use to bipolar disorder and Alzheimer's agitation, with ongoing studies.

OSE Immunotherapeutics reports H1 2024 results with €82.5 million income, strategic partnerships with AbbVie and Boehringer Ingelheim, and €80.7 million cash position. Clinical highlights include positive Phase 1/2 results for OSE-279 and Lusvertikimab, and the launch of the Artemia Phase 3 study for Tedopi®.

FDA approves AstraZeneca's Tagrisso for stage 3 EGFR-mutated NSCLC previously treated with chemoradiotherapy, based on LAURA trial showing 84% reduction in disease progression risk.

Weekend warrior workouts offer similar health benefits to daily exercise, reducing risk of over 200 diseases, according to a study in 'Circulation'. Both patterns lower risks for conditions like high blood pressure and diabetes, suggesting total activity volume is key.

Inebilizumab-cdon shows efficacy in treating IgG4-related disease and generalized myasthenia gravis in phase 3 trials, reducing flare risk by 87% and improving daily activities, with no new safety signals identified.